Backed by Main Sequence & CSIRO
XYLO
Targeted next-gen therapeutics designed to restore brain function
XYLO is pioneering neuroplastogen therapies that rewire neural circuits and restore brain function without hallucinatory effects. Their computationally enhanced drug discovery platform designs highly targeted small molecules for psychiatric and neurological disorders, with lead candidate XYL-1001 heading to first-in-human trials.
Rewiring the Brain, Without Hallucinations
XYLO's computationally enhanced platform designs non-hallucinogenic neuroplastogens that stimulate the growth and remodelling of neural circuits, addressing the underlying dysfunction rather than merely managing symptoms.
Backed by Main Sequence & CSIRO
Ready to learn more about XYLO?
Discover how XYLO is transforming their industry with deep technology innovation.